Mon, October 17, 2022
Sat, October 15, 2022
Fri, October 14, 2022
Thu, October 13, 2022
Wed, October 12, 2022
Tue, October 11, 2022

Matthew Harrison Maintained (BMRN) at Buy with Decreased Target to $111 on, Oct 13th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. th-decreased-target-to-111-on-oct-13th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Matthew Harrison of Morgan Stanley, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Decreased Target from $117 to $111 on, Oct 13th, 2022.

Matthew has made no other calls on BMRN in the last 4 months.



There are 5 other peers that have a rating on BMRN. Out of the 5 peers that are also analyzing BMRN, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Andreas Argyrides of "Wedbush" Initiated at Hold and Held Target at $70 on, Monday, June 13th, 2022


These are the ratings of the 4 analyists that currently disagree with Matthew


  • Christopher Raymond of "Piper Sandler" Maintained at Buy with Increased Target to $128 on, Tuesday, August 9th, 2022
  • Gena Wang of "Barclays" Maintained at Buy with Increased Target to $125 on, Thursday, August 4th, 2022
  • Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $122 on, Thursday, August 4th, 2022
  • Olivia Brayer of "Cantor Fitzgerald" Initiated at Buy and Held Target at $110 on, Wednesday, July 13th, 2022

Publication Contributing Sources